Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2011

01-12-2011 | Original Article

Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience

Authors: Atsunari Kawashima, Masashi Nakayama, Daizo Oka, Mototaka Sato, Koji Hatano, Masatoshi Mukai, Akira Nagahara, Yasutomo Nakai, Hitoshi Takayama, Masayoshi Inoue, Hiroyuki Shiono, Kazuo Nishimura, Meinoshin Okumura, Norio Nonomura

Published in: International Journal of Clinical Oncology | Issue 6/2011

Login to get access

Abstract

Background

Pulmonary metastasectomy in patients with renal cell carcinoma (RCC) remains controversial. The purpose of our analysis was to explore the outcome of patients with RCC who underwent pulmonary metastasectomy at our institution.

Methods

We reviewed data on 25 patients who underwent resection of lung metastasis from 1998 to 2008 at our institution.

Results

All patients were treated by radical nephrectomy for primary RCC. Progression-free survival (PFS) ranged from 0.3 to 198.8 months (median 7.4 months), and overall survival (OS) ranged from 2.4 to 198.8 months (median 33.9 months). The 5-year PFS rate was 24.9%, and the OS rate was 35.5%. Although differences in the resectability of the metastasectomy and OS were not significant in univariate or multivariate analyses, the relationship between PFS and the radicality of pulmonary metastasectomy was significant in both the univariate and multivariate analyses (P = 0.004, 0.012, respectively).

Conclusions

The results of pulmonary metastasectomy for patients with RCC at our institution indicate that pulmonary metastasectomy should be performed only when the pulmonary metastasis can be completely resected. Additional studies are therefore necessary to evaluate the prognostic factors and to determine the selection criteria for pulmonary metastasectomy in the new era of molecular-targeted agents.
Literature
1.
Henriksson C, Haraldsson G, Aldenborg F et al (1992) Skeletal metastases in 102 patients evaluated before surgery for renal cell carcinoma. Scand J Urol Nephrol 26:363–366PubMedCrossRef
2.
Giuliani L, Giberti C, Martorana G et al (1990) Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143:468–474PubMed
3.
de Kernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120:48
4.
Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353:2477–2490
5.
Bellmunt J, Montagut C, Albiol et al (2007) Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 99:274–280
6.
Lane BR, Rini Bi, Novick AC et al (2007) Targeted molecular therapy for renal cell carcinoma. Urology 69:3–10PubMedCrossRef
7.
Akaza H, Tsukamoto T, Murai M et al (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755–762PubMedCrossRef
8.
Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastases to the lung. J Urol 42:269–276
9.
van der Poel HG, Roukema JA, Horenblas S et al (1999) Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol 35:197–203PubMedCrossRef
10.
Hofmann HS, Neef H, Krohe K et al (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48:77–82PubMedCrossRef
11.
Assouad J, Petkova B, Berna P et al (2007) Renal cell carcinoma lung metastases: pathologic findings and prognostic factors. Ann Thorac Surg 84:1114–1120PubMedCrossRef
12.
Chen F, Fujinaga T, Shoji T et al (2008) Pulmonary resection for metastasis from renal cell carcinoma. Interact Cardiovasc Thorac Surg 7:825–828PubMedCrossRef
13.
Kanazaki R, Higashiyama M, Fujiwara A et al (2011) Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg 39:167–172CrossRef
14.
Guinan P, Sobin LH, Algaba F et al (1997) TNM staging of renal cell carcinoma: Workgroup No. 3. Cancer 80:992–993PubMedCrossRef
15.
Staehler MD, Kruse J, Haseke N et al (2010) Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol 28:543–547
16.
Reddy S, Wolfgang CL (2009) The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol 10:287–293PubMedCrossRef
17.
Fujioka T, Obara W, Miki T et al (2009) Evidence-based clinical practice guidelines for renal cell carcinoma (Summary—JUA 2007). Int J Urol 16:339–353PubMed
18.
Assouad J, Banu E, Brian E et al (2008) Strategies and outcomes in pulmonary and extrapulmonary metastases from renal cell cancer. Eur J Cardiothorac Surg 33:794–798PubMedCrossRef
19.
Loehe F, Kobinger S, Hatz RA et al (2001) Value of systematic mediastinal lymph node dissection during pulmonary metastasectomy. Ann Thorac Surg 72:225PubMedCrossRef
20.
Cerfolio RJ, Allen MS, Deschamps C et al (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57:339–344PubMedCrossRef
21.
Friedel G, Hurtgen M, Penzenstadler M et al (1999) Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res 19:1593–1596PubMed
22.
Plitz S, Meimarakis G, Wichmann MW et al (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 73:1082–1087CrossRef
23.
Pfannschmidt J, Hoffmann H, Muley T et al (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74:1653–1657PubMedCrossRef
24.
Sherry RM, Pass HI, Rosenberg SA et al (1992) Surgical resection of metastatic renal cell carcinoma and melanoma after response to interlerukin-2-based immunotherapy. Cancer 69:1850–1855PubMedCrossRef
25.
Kim B, Louie AC (1992) Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 127:1343–1349PubMedCrossRef
26.
Naito S, Yamamoto N, Takayama T et al (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57:317–326PubMedCrossRef
27.
Motzer RJ, Basch E (2007) Targeted drugs of metastatic renal cell carcinoma. Lancet 370:2071–2073PubMedCrossRef
Metadata
Title
Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience
Authors
Atsunari Kawashima
Masashi Nakayama
Daizo Oka
Mototaka Sato
Koji Hatano
Masatoshi Mukai
Akira Nagahara
Yasutomo Nakai
Hitoshi Takayama
Masayoshi Inoue
Hiroyuki Shiono
Kazuo Nishimura
Meinoshin Okumura
Norio Nonomura
Publication date
01-12-2011
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0244-0

Other articles of this Issue 6/2011

International Journal of Clinical Oncology 6/2011 Go to the issue

Original Article

Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells

Original Article

A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma

Original Article

Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes

Case Report

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors

Case Report

A case of primary alveolar soft part sarcoma of the uterine cervix and a review of the literature

Original Article

The prevalence of human papillomavirus in oral premalignant lesions and squamous cell carcinoma in comparison to cervical lesions used as a positive control
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits